Singapore, May 1 -- In the dynamic landscape of healthcare, where clinical trials represent the cornerstone of medical progress, startups have emerged as key drivers of change. The clinical trials market in India was estimated to be valued at $2.07 billion in 2022, and it is expected to expand at a compound annual growth rate (CAGR) of 8.2 per cent from 2022 to 2030, reaching $3.88 billion by 2030. This exponential growth not only reflects the country's evolving medical infrastructure but also underscores the pivotal role of innovative startups in redefining the healthcare landscape.

Despite India's status as Asia's fourth-largest medical equipment manufacturer and its 8 per cent share in the global medtech research and development workf...